Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
<p>Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways b...
Uloženo v:
| Hlavní autor: | James S. Wilmott (15008931) (author) |
|---|---|
| Další autoři: | Hussein Tawbi (15054769) (author), Johnathan A. Engh (15054772) (author), Nduka M. Amankulor (15054775) (author), Brindha Shivalingam (15054778) (author), Hiya Banerjee (15054781) (author), Ismael A. Vergara (15054784) (author), Hansol Lee (15054787) (author), Peter A. Johansson (15054790) (author), Peter M. Ferguson (15054793) (author), Philippe Saiag (15054796) (author), Caroline Robert (15032672) (author), Jean-Jacques Grob (15054799) (author), Lisa H. Butterfield (15035537) (author), Richard A. Scolyer (10778711) (author), John M. Kirkwood (15023483) (author), Georgina V. Long (11420813) (author), Michael A. Davies (14932995) (author) |
| Vydáno: |
2025
|
| Témata: | |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Podobné jednotky
-
Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Autor: James S. Wilmott (15008931)
Vydáno: (2025) -
Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Autor: Qingsheng Xu (17078830)
Vydáno: (2025) -
Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Autor: Qingsheng Xu (17078830)
Vydáno: (2025) -
Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Autor: Tom Wei-Wu Chen (15053003)
Vydáno: (2025) -
Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Autor: Tom Wei-Wu Chen (15053003)
Vydáno: (2025)